Precision Medicine

A new clinical trial is underway for a next-gen aortic valve, promising a less invasive procedure and improved durability for millions of patients.

With stellar trial data for its cholesterol drug obicetrapib, NewAmsterdam Pharma faces investors as it navigates a competitive market and awaits key results.

With its future riding on a pivotal trial for avexitide, Amylyx's upcoming conference presentation offers a crucial look into its post-ALS strategy.

Blue Faery recognizes two doctors whose groundbreaking research in immunotherapy and targeted drugs has created new standards of care for liver cancer patients.

FDA approves a pivotal trial for a novel heart valve, potentially revolutionizing treatment for millions with severe tricuspid regurgitation.

As lung cancer becomes a growing crisis for women, the LCRF gala honors two leaders driving change and rallying support for life-saving research.

A new bispecific antibody aims to treat the 50% of AxSpA patients who find no relief, as Fortitude Biomedicines enters a competitive autoimmune market.

Ontario and Quebec expand public coverage for a potent cholesterol drug, offering a critical lifeline to thousands at risk of a second cardiovascular event.

AIRNA has dosed the first patient with AIR-001, an RNA-editing drug that could treat both the lung and liver damage of a devastating genetic disease.

The firm adds veteran TD Cowen analyst Boris Peaker to deepen its research in oncology and genetic medicines, signaling a major bet on specialized insight.

In a major strategic move, Premier Research appoints Paul Spreen as CCO, signaling a bold push to capture the rebounding biotech market.

A new trial for advanced liver cancer tests visugromab, a drug aiming to overcome immunotherapy resistance and reverse debilitating cancer-related wasting.

A novel interferon-based therapy from ABION shows promise in preclinical studies, overcoming resistance to current cancer drugs and activating the immune system.

With a new president at the helm, PDS Health Medical plans an aggressive national expansion of its model that unites dental and primary care under one roof.

Boston's Bio-IT World conference shifts from AI theory to execution, showcasing how the life sciences industry is now deploying AI to accelerate new therapies.

This April, families nationwide are walking to fund a new strategy for Lennox-Gastaut Syndrome, aiming to slash diagnosis times and find real cures.

Apnimed has secured up to $150M to launch AD109, a potential first-ever pill for sleep apnea, promising relief for millions tired of CPAP machines.

MTI replaces its Road Tour with an intense, invite-only forum, uniting top regulators and experts to find the next wave of healthcare solutions.

Biopharma firm GENFIT sees soaring Iqirvo sales and a cash runway past 2028, overshadowing a net loss driven by strategic, non-cash write-downs.

A new partnership brings FDA-cleared eye-tracking tech to more providers, promising to cut year-long waits for autism diagnosis to mere minutes.